The stock has demonstrated a strong overall uptrend over the past six months, rising approximately 15.3% from a close of $49.51 on October 2, 2025, to $57.07 on March 31, 2026. This performance significantly outpaced the broader market, as indicated by a positive 6-month relative strength of 18.09. Short-term performance shows resilience; the stock gained 6.93% over the last three months despite a 3.17% decline over the past month. The recent one-month pullback was less severe than the S&P 500's 5.25% drop, resulting in positive relative strength of 2.08 for that period. The current price of $57.07 is near the upper end of its 52-week range of $44.60 to $59.98, trading about 4.9% below the yearly high. The price has retreated from a recent peak near $59.17 in late March, indicating potential consolidation at elevated levels.

Revenue for Q4 2025 was $3.10 billion, representing a 9.05% year-over-year growth from the same quarter in 2024. Profitability remains robust, with a net margin of 41.6% and an operating margin of 40.3% for the latest period, though quarterly net income of $1.19 billion was below the $1.55 billion reported in Q3 2025. Financial health is characterized by a high debt-to-equity ratio of 1.83, which is typical for capital-intensive midstream entities. The company generates substantial cash flow, with free cash flow over the trailing twelve months at $5.20 billion, comfortably covering dividend payments. Operational efficiency is strong, as evidenced by a high return on equity (ROE) of 34.35% and a return on assets (ROA) of 7.39%. The current ratio of 1.23 indicates adequate short-term liquidity to meet its obligations.